Literature DB >> 30790076

Fc Receptors in Antimicrobial Protection.

Andreas Wieland1, Rafi Ahmed2.   

Abstract

Antibodies are the key effector molecules of the humoral immune system providing long-term protective immunity against a wide range of pathogens and regulating immune responses. Traditionally, antibody-mediated protection against microbes was thought to be mainly a result of neutralizing Fab-antigen interaction; however, an increasing number of studies show the importance of proper FcR engagement for the protective capacity of antimicrobial antibodies. In this chapter, we review FcR-mediated effector functions contributing to antimicrobial protection in a direct and indirect manner. Furthermore, we highlight recent findings about the important role of Fc-FcR interactions for antimicrobial protection in vivo and provide examples demonstrating the crucial role of proper FcR engagement for antibody-mediated protection against viruses, bacteria, fungi, and parasites.

Mesh:

Substances:

Year:  2019        PMID: 30790076     DOI: 10.1007/82_2019_154

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  5 in total

1.  Persistence of Virus-Specific Antibody after Depletion of Memory B Cells.

Authors:  William A Langley; Andreas Wieland; Hasan Ahmed; Mohammed Ata Ur Rasheed; Carl W Davis; Jaturong Sewatanon; Scott N Mueller; Mark J Shlomchik; Veronika I Zarnitsyna; Rustom Antia; Rafi Ahmed
Journal:  J Virol       Date:  2022-04-11       Impact factor: 6.549

2.  Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.

Authors:  Shihui Sun; Lei He; Zhongpeng Zhao; Hongjing Gu; Xin Fang; Tiecheng Wang; Xiaolan Yang; Shaolong Chen; Yongqiang Deng; Jiangfan Li; Jian Zhao; Liang Li; Xinwang Li; Peng He; Ge Li; Hao Li; Yuee Zhao; Chunrun Gao; Xiaoling Lang; Xin Wang; Guoqiang Fei; Yan Li; Shusheng Geng; Yuwei Gao; Wenjin Wei; Zhongyu Hu; Gencheng Han; Yansong Sun
Journal:  Cell Mol Immunol       Date:  2021-03-17       Impact factor: 11.530

3.  A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults.

Authors:  Deyan Luo; Hongxing Pan; Peng He; Xiaolan Yang; Tao Li; Nianzhi Ning; Xin Fang; Wenjing Yu; Mingwei Wei; Hui Gao; Xin Wang; Hongjing Gu; Maodong Mei; Xinwang Li; Liangyan Zhang; Deyu Li; Chunrun Gao; Jinbang Gao; Guoqiang Fei; Ying Li; Yuguo Yang; Yi Xu; Wenjin Wei; Yansong Sun; Fengcai Zhu; Zhongyu Hu; Hui Wang
Journal:  Clin Transl Med       Date:  2022-09

4.  CCN1 is an opsonin for bacterial clearance and a direct activator of Toll-like receptor signaling.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Commun       Date:  2020-03-06       Impact factor: 14.919

5.  Defining HPV-specific B cell responses in patients with head and neck cancer.

Authors:  Andreas Wieland; Mihir R Patel; Maria A Cardenas; Christiane S Eberhardt; William H Hudson; Rebecca C Obeng; Christopher C Griffith; Xu Wang; Zhuo G Chen; Haydn T Kissick; Nabil F Saba; Rafi Ahmed
Journal:  Nature       Date:  2020-11-18       Impact factor: 69.504

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.